TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma
In 2013, The Cancer Genome Atlas (TCGA) Research Network found four novel prognostic subgroups of endometrial carcinoma: POLE/ultramutated (POLE), microsatellite-instable/hypermutated (MSI), copy-number-low/TP53-wild-type (CNL), and copy-number-highTP53-mutant (CNH). However, poor is known regarding...
Gespeichert in:
| Veröffentlicht in: | Pathology oncology research 2020-10, Vol.26 (4), p.2067-2073 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2073 |
|---|---|
| container_issue | 4 |
| container_start_page | 2067 |
| container_title | Pathology oncology research |
| container_volume | 26 |
| creator | Travaglino, Antonio Raffone, Antonio Gencarelli, Annarita Mollo, Antonio Guida, Maurizio Insabato, Luigi Santoro, Angela Zannoni, Gian Franco Zullo, Fulvio |
| description | In 2013, The Cancer Genome Atlas (TCGA) Research Network found four novel prognostic subgroups of endometrial carcinoma: POLE/ultramutated (POLE), microsatellite-instable/hypermutated (MSI), copy-number-low/TP53-wild-type (CNL), and copy-number-highTP53-mutant (CNH). However, poor is known regarding uncommon histotypes of endometrial cancer. We aimed to assess the genetic profile of uterine carcinosarcoma (UCS) on the light of these findings. A systematic review and meta-analysis was performed through electronic databases searching (up to July 2019). All studies assessing UCS series for the TCGA classification were included. For each TCGA subgroup, pooled prevalence on the total UCS number was calculated. Four studies with 231 patients were included. Pooled prevalence of the TCGA subgroups were: 5.3% for the POLE subgroup, 7.3% for the MSI subgroup, 73.9% for the CNH subgroup, 13.5% for the CNL subgroup. The CNH subgroup predominates in UCS, while subgroups with high mutational load (POLE and MSI) are less common. UCS appears as a preferential evolution of CNH carcinomas. |
| doi_str_mv | 10.1007/s12253-020-00829-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2408191063</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2408191063</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-d264feb4f98b0527658f073eb2fd79bcef32e3ec28e8cbfaf7736f884da9e62c3</originalsourceid><addsrcrecordid>eNp9kMtKxTAQhoMo3l_AhRTcuKkmkzRN3Ek5XkDQha5Dmk600jaa9Cx8e6PHC7hwNYF8_z_DR8gBoyeM0vo0MYCKlxRoSakCXeo1ss0qDiUoWq_nNzBdCl3JLbKT0jPNIanlJtniIGoQgm2Ti_vm8rxoBptS73tn5z5MRfDFYurCiHPs7VA0dnIYz4r5CYu7wTr8ABobXT-FlEcY7R7Z8HZIuP81d8nDxeK-uSpvbi-vm_Ob0uVtc9mBFB5b4bVqaQW1rJSnNccWfFfr1qHngBwdKFSu9dbXNZdeKdFZjRIc3yXHq96XGF6XmGYz9snhMNgJwzIZEFQxzajkGT36gz6HZZzydZkSlAKXWmQKVpSLIaWI3rzEfrTxzTBqPiyblWWTLZtPy0bn0OFX9bIdsfuJfGvNAF8BKX9Njxh_d_9T-w4NPIZZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2440023694</pqid></control><display><type>article</type><title>TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma</title><source>SpringerLink Journals</source><creator>Travaglino, Antonio ; Raffone, Antonio ; Gencarelli, Annarita ; Mollo, Antonio ; Guida, Maurizio ; Insabato, Luigi ; Santoro, Angela ; Zannoni, Gian Franco ; Zullo, Fulvio</creator><creatorcontrib>Travaglino, Antonio ; Raffone, Antonio ; Gencarelli, Annarita ; Mollo, Antonio ; Guida, Maurizio ; Insabato, Luigi ; Santoro, Angela ; Zannoni, Gian Franco ; Zullo, Fulvio</creatorcontrib><description>In 2013, The Cancer Genome Atlas (TCGA) Research Network found four novel prognostic subgroups of endometrial carcinoma: POLE/ultramutated (POLE), microsatellite-instable/hypermutated (MSI), copy-number-low/TP53-wild-type (CNL), and copy-number-highTP53-mutant (CNH). However, poor is known regarding uncommon histotypes of endometrial cancer. We aimed to assess the genetic profile of uterine carcinosarcoma (UCS) on the light of these findings. A systematic review and meta-analysis was performed through electronic databases searching (up to July 2019). All studies assessing UCS series for the TCGA classification were included. For each TCGA subgroup, pooled prevalence on the total UCS number was calculated. Four studies with 231 patients were included. Pooled prevalence of the TCGA subgroups were: 5.3% for the POLE subgroup, 7.3% for the MSI subgroup, 73.9% for the CNH subgroup, 13.5% for the CNL subgroup. The CNH subgroup predominates in UCS, while subgroups with high mutational load (POLE and MSI) are less common. UCS appears as a preferential evolution of CNH carcinomas.</description><identifier>ISSN: 1219-4956</identifier><identifier>EISSN: 1532-2807</identifier><identifier>DOI: 10.1007/s12253-020-00829-9</identifier><identifier>PMID: 32472441</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Carcinoma ; Classification ; Endometrial cancer ; Endometrium ; Genomes ; Immunology ; Medical prognosis ; Oncology ; p53 Protein ; Pathology ; Review ; Uterine cancer ; Uterus</subject><ispartof>Pathology oncology research, 2020-10, Vol.26 (4), p.2067-2073</ispartof><rights>Arányi Lajos Foundation 2020</rights><rights>Arányi Lajos Foundation 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-d264feb4f98b0527658f073eb2fd79bcef32e3ec28e8cbfaf7736f884da9e62c3</citedby><cites>FETCH-LOGICAL-c441t-d264feb4f98b0527658f073eb2fd79bcef32e3ec28e8cbfaf7736f884da9e62c3</cites><orcidid>0000-0001-5443-2333</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12253-020-00829-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12253-020-00829-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32472441$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Travaglino, Antonio</creatorcontrib><creatorcontrib>Raffone, Antonio</creatorcontrib><creatorcontrib>Gencarelli, Annarita</creatorcontrib><creatorcontrib>Mollo, Antonio</creatorcontrib><creatorcontrib>Guida, Maurizio</creatorcontrib><creatorcontrib>Insabato, Luigi</creatorcontrib><creatorcontrib>Santoro, Angela</creatorcontrib><creatorcontrib>Zannoni, Gian Franco</creatorcontrib><creatorcontrib>Zullo, Fulvio</creatorcontrib><title>TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma</title><title>Pathology oncology research</title><addtitle>Pathol. Oncol. Res</addtitle><addtitle>Pathol Oncol Res</addtitle><description>In 2013, The Cancer Genome Atlas (TCGA) Research Network found four novel prognostic subgroups of endometrial carcinoma: POLE/ultramutated (POLE), microsatellite-instable/hypermutated (MSI), copy-number-low/TP53-wild-type (CNL), and copy-number-highTP53-mutant (CNH). However, poor is known regarding uncommon histotypes of endometrial cancer. We aimed to assess the genetic profile of uterine carcinosarcoma (UCS) on the light of these findings. A systematic review and meta-analysis was performed through electronic databases searching (up to July 2019). All studies assessing UCS series for the TCGA classification were included. For each TCGA subgroup, pooled prevalence on the total UCS number was calculated. Four studies with 231 patients were included. Pooled prevalence of the TCGA subgroups were: 5.3% for the POLE subgroup, 7.3% for the MSI subgroup, 73.9% for the CNH subgroup, 13.5% for the CNL subgroup. The CNH subgroup predominates in UCS, while subgroups with high mutational load (POLE and MSI) are less common. UCS appears as a preferential evolution of CNH carcinomas.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Carcinoma</subject><subject>Classification</subject><subject>Endometrial cancer</subject><subject>Endometrium</subject><subject>Genomes</subject><subject>Immunology</subject><subject>Medical prognosis</subject><subject>Oncology</subject><subject>p53 Protein</subject><subject>Pathology</subject><subject>Review</subject><subject>Uterine cancer</subject><subject>Uterus</subject><issn>1219-4956</issn><issn>1532-2807</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kMtKxTAQhoMo3l_AhRTcuKkmkzRN3Ek5XkDQha5Dmk600jaa9Cx8e6PHC7hwNYF8_z_DR8gBoyeM0vo0MYCKlxRoSakCXeo1ss0qDiUoWq_nNzBdCl3JLbKT0jPNIanlJtniIGoQgm2Ti_vm8rxoBptS73tn5z5MRfDFYurCiHPs7VA0dnIYz4r5CYu7wTr8ABobXT-FlEcY7R7Z8HZIuP81d8nDxeK-uSpvbi-vm_Ob0uVtc9mBFB5b4bVqaQW1rJSnNccWfFfr1qHngBwdKFSu9dbXNZdeKdFZjRIc3yXHq96XGF6XmGYz9snhMNgJwzIZEFQxzajkGT36gz6HZZzydZkSlAKXWmQKVpSLIaWI3rzEfrTxzTBqPiyblWWTLZtPy0bn0OFX9bIdsfuJfGvNAF8BKX9Njxh_d_9T-w4NPIZZ</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Travaglino, Antonio</creator><creator>Raffone, Antonio</creator><creator>Gencarelli, Annarita</creator><creator>Mollo, Antonio</creator><creator>Guida, Maurizio</creator><creator>Insabato, Luigi</creator><creator>Santoro, Angela</creator><creator>Zannoni, Gian Franco</creator><creator>Zullo, Fulvio</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5443-2333</orcidid></search><sort><creationdate>20201001</creationdate><title>TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma</title><author>Travaglino, Antonio ; Raffone, Antonio ; Gencarelli, Annarita ; Mollo, Antonio ; Guida, Maurizio ; Insabato, Luigi ; Santoro, Angela ; Zannoni, Gian Franco ; Zullo, Fulvio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-d264feb4f98b0527658f073eb2fd79bcef32e3ec28e8cbfaf7736f884da9e62c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Carcinoma</topic><topic>Classification</topic><topic>Endometrial cancer</topic><topic>Endometrium</topic><topic>Genomes</topic><topic>Immunology</topic><topic>Medical prognosis</topic><topic>Oncology</topic><topic>p53 Protein</topic><topic>Pathology</topic><topic>Review</topic><topic>Uterine cancer</topic><topic>Uterus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Travaglino, Antonio</creatorcontrib><creatorcontrib>Raffone, Antonio</creatorcontrib><creatorcontrib>Gencarelli, Annarita</creatorcontrib><creatorcontrib>Mollo, Antonio</creatorcontrib><creatorcontrib>Guida, Maurizio</creatorcontrib><creatorcontrib>Insabato, Luigi</creatorcontrib><creatorcontrib>Santoro, Angela</creatorcontrib><creatorcontrib>Zannoni, Gian Franco</creatorcontrib><creatorcontrib>Zullo, Fulvio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pathology oncology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Travaglino, Antonio</au><au>Raffone, Antonio</au><au>Gencarelli, Annarita</au><au>Mollo, Antonio</au><au>Guida, Maurizio</au><au>Insabato, Luigi</au><au>Santoro, Angela</au><au>Zannoni, Gian Franco</au><au>Zullo, Fulvio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma</atitle><jtitle>Pathology oncology research</jtitle><stitle>Pathol. Oncol. Res</stitle><addtitle>Pathol Oncol Res</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>26</volume><issue>4</issue><spage>2067</spage><epage>2073</epage><pages>2067-2073</pages><issn>1219-4956</issn><eissn>1532-2807</eissn><abstract>In 2013, The Cancer Genome Atlas (TCGA) Research Network found four novel prognostic subgroups of endometrial carcinoma: POLE/ultramutated (POLE), microsatellite-instable/hypermutated (MSI), copy-number-low/TP53-wild-type (CNL), and copy-number-highTP53-mutant (CNH). However, poor is known regarding uncommon histotypes of endometrial cancer. We aimed to assess the genetic profile of uterine carcinosarcoma (UCS) on the light of these findings. A systematic review and meta-analysis was performed through electronic databases searching (up to July 2019). All studies assessing UCS series for the TCGA classification were included. For each TCGA subgroup, pooled prevalence on the total UCS number was calculated. Four studies with 231 patients were included. Pooled prevalence of the TCGA subgroups were: 5.3% for the POLE subgroup, 7.3% for the MSI subgroup, 73.9% for the CNH subgroup, 13.5% for the CNL subgroup. The CNH subgroup predominates in UCS, while subgroups with high mutational load (POLE and MSI) are less common. UCS appears as a preferential evolution of CNH carcinomas.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>32472441</pmid><doi>10.1007/s12253-020-00829-9</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-5443-2333</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1219-4956 |
| ispartof | Pathology oncology research, 2020-10, Vol.26 (4), p.2067-2073 |
| issn | 1219-4956 1532-2807 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2408191063 |
| source | SpringerLink Journals |
| subjects | Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma Classification Endometrial cancer Endometrium Genomes Immunology Medical prognosis Oncology p53 Protein Pathology Review Uterine cancer Uterus |
| title | TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T10%3A29%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TCGA%20Classification%20of%20Endometrial%20Cancer:%20the%20Place%20of%20Carcinosarcoma&rft.jtitle=Pathology%20oncology%20research&rft.au=Travaglino,%20Antonio&rft.date=2020-10-01&rft.volume=26&rft.issue=4&rft.spage=2067&rft.epage=2073&rft.pages=2067-2073&rft.issn=1219-4956&rft.eissn=1532-2807&rft_id=info:doi/10.1007/s12253-020-00829-9&rft_dat=%3Cproquest_cross%3E2408191063%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2440023694&rft_id=info:pmid/32472441&rfr_iscdi=true |